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Abstract: Even after countered with and responding to maximal surgical and chemotherapy 
efforts, advanced ovarian cancer usually ultimately recurs. One strategy employed to forestall 
recurrence is maintenance chemotherapy, an extension of treatment following a complete response 
to conventional measures. Many agents have been studied and many more are currently under 
investigation in maintenance regimens. While phase III data suggest that taxane maintenance 
prolongs progression-free survival, no overall survival benefit has been established. This 
article reviews the current status of maintenance therapy for advanced ovarian cancer, including 
phase III evidence and new and upcoming trials.
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Introduction
Ovarian cancer continues to be associated with very high morbidity and mortality. 
In 2009, there will be an estimated 21,550 new cases of ovarian cancer diagnosed in 
the United States and 14,600 deaths.1 Even with optimal frontline treatment involv-
ing aggressive surgical cytoreduction followed by platinum and taxane-based 
chemotherapy, 5-year survival for women with advanced stage disease is only 
45%. Furthermore, over 50% of women who achieve a complete response to ini-
tial treatment will relapse within 18 to 24 months.2 While effective second-line 
treatments are available, response rates drop with each subsequent recurrence 
due to the onset of drug resistance. From this background, the notion of extended 
chemotherapy following complete response to conventional treatment has been 
developed in an effort to delay or even avoid recurrence completely.
Definitions
Two basic approaches have been taken to extended chemotherapy: 1) consolidation 
or intensification therapy, and 2) maintenance chemotherapy. These terms are 
indistinct and often confused in the literature. Consolidation therapy generally 
involves the addition of an intense short-term treatment immediately following the 
completion of front-line therapy. Whole abdominal radiation, radioimmunotherapy, 
intraperitoneal chromic phosphate (32P), and high-dose cytotoxic chemotherapy 
with stem cell support have all been studied with little proven benefit but with 
substantial toxicity for ovarian cancer patients (see Table 1).3–18 Maintenance 
chemotherapy, on the other hand, involves lower-dose treatments over a more 
prolonged period following a clinical remission from a standard regimen. The data International Journal of Women’s Health 2009:1 174
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here are more promising, and a review of the phase III 
evidence is the subject of this paper.
Rationale
The rationale supporting maintenance chemotherapy is 
based on the theory that slowly dividing tumor cells which 
were inadequately exposed to front-line cycle-dependent 
cytotoxic treatment may be effectively eliminated by 
continued treatment over time.19,20 In addition to targeting 
the remaining tumor burden, prolonged chemotherapy 
with known antiangiogenic agents may forestall new tumor 
growth. Opponents of maintenance therapy argue that resting 
after primary chemotherapy allows for recovery from the 
toxic effects, and that waiting for recurrence increases the 
likelihood of repopulation with chemo-responsive cells. 
These arguments are founded in the concern that main-
tenance treatment may obviate the benefit of retreatment 
when relapse occurs.6 Randomized controlled data have yet 
to resolve this debate definitively. Additionally, the effect of 
maintenance therapy on quality of life needs to be considered 
when making decisions about continuing or stopping 
treatment once complete response is reached.
Phase III clinical trials: a historical 
perspective
In the 1990s, several randomized trials addressed the question 
of whether extending the number of platinum cycles during 
front-line chemotherapy would benefit survival. Eight, 
10, and 12 cycles were compared to the standard of 5 or 6, 
and no improvement in response or prolongation of survival 
was established.4–6 Patients in these trials were randomized 
prior to initiation of front-line treatment rather than after 
determination of clinical response. Therefore, platinum-
resistant patients (roughly 25% of women with ovarian 
cancer) were randomized to receive more of a drug to which 
they were probably not responding in the first place. Further-
more, the cumulative toxicity of extended platinum therapy 
made it a questionable choice as a maintenance agent.
Many subsequent trials have sought to avoid similar 
design flaws by establishing documented complete clinical 
response as inclusion criteria. However, phase III trials 
of extended treatment with topotecan, whole-abdominal 
radiation, intraperitoneal 32P, high-dose cytotoxic regimens, 
antiangiogenic matrix metalloproteinase inhibitors, and 
immunotherapies such as interferon alpha have all failed 
to demonstrate survival advantages (Table 1).3,7–16 The only 
positive randomized controlled data to date involve the 
use of paclitaxel. Taxanes are compelling as maintenance 
agents because in addition to being cytotoxic, they have 
antiangiogenic activity which may be enhanced by prolonged 
and effectively spaced treatments.17,18
In 2003, Markman et al published initial results from 
the SWOG S9761/GOG 178 collaborative trial in which 
advanced stage ovarian cancer patients with complete 
clinical response to platinum/taxane therapy were random-
ized to receive either 3 or 12 cycles of monthly paclitaxel 
(175 mg/m2 in a 3-hour infusion).17 At the interim analysis, 
34/112 patients in the 3-cycle arm had relapsed, compared 
to 20/110 patients in the 12-cycle arm (P = 0.0023), trans-
lating to a median progression-free survival advantage of 
7 months (21 vs 28 months). The SWOG data safety and 
monitoring committee discontinued the trial on basis of a 
prespecified termination boundary of P = 0.005. At the time 
the study was closed, no significant overall survival advan-
tage was demonstrable.17
In 2009, mature results from GOG 178 were published, 
confirming an 8-month progression-free survival advan-
tage in the 12-cycle arm (22 vs 14 months, P = 0.006), 
but failing to establish a overall survival advantage (53 vs 
48 months, P = 0.34).18 The authors hypothesized that a 
potential survival advantage may have been obviated by 1) 
insufficient sample size, 2) crossover patients in the 3-cycle 
arm who actually received more cycles (6%, or 9 patients), 
or 3) the equalizing effects of treatments initiated once 
relapse occurred. Of note, a second randomized trial of 
paclitaxel maintenance conducted by Conte et al failed to 
show either progression-free survival or overall survival 
benefit. In this trial, 200 advanced ovarian cancer patients 
with complete response to platinum/paclitaxel treatment 
were randomized to single-agent paclitaxel every 3 weeks 
for 6 cycles versus observation. At 44 months, median 
progression-free survival and 3-year overall survival were 
34 months and 88%, respectively, in the observation arm, 
compared to 34.5 months and 78% in the paclitaxel arm.16
Ongoing randomized controlled trials
Several ongoing phase III clinical trials have been 
designed to determine whether maintenance chemotherapy 
confers a survival advantage in ovarian cancer patients 
(see Table 2). The taxane question will be addressed directly 
by GOG 212 – a 3-arm randomized trial of maintenance 
chemotherapy comparing 12 months of single-agent pacli-
taxel to polyglutamate paclitaxel (XyotaxTM, or PPX) or 
observation alone until documented relapse in stage III or IV 
ovarian epithelial ovarian or peritoneal cancers. PPX is a drug 
conjugate which links poly-L-glutamic acid, a biodegradable International Journal of Women’s Health 2009:1 176
Hope and Blank Dovepress
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polymer, to paclitaxel. The conjugate confers molecular 
stability within the systemic circulation and enhances passive 
accumulation in tumor tissue where PPX progressively 
releases its active taxane constituent.22 Eligibility includes 
optimally surgically cyto-reduced patients (1 cm of residual 
disease) who have had a complete response to adjuvant 
platinum/taxane treatment as well as patients who have 
received neoadjuvant chemotherapy followed by surgery to 
no residual disease. Primary outcome of this trial is overall 
survival. Secondary outcomes include quality of life, periph-
eral neuropathy, and a series of exploratory angiogenic 
markers.23
The use of biologic agents for maintenance therapy 
in both front-line and recurrent settings is currently the 
focus of avid ovarian cancer research. Bevacizumab is 
a humanized recombinant monoclonal antibody, which 
targets vascular endothelial growth factor (VEGF), an 
important factor in tumor angiogenesis. Preclinically, mouse 
xenograft models have demonstrated that bevacizumab 
inhibits recurrence and prolongs survival when given as 
maintenance therapy 3 weeks after induction combination 
chemotherapy.24 Bevacizumab maintenance is addressed in 
GOG 218, a randomized controlled trial in which advanced 
ovarian, primary peritoneal, and fallopian tube cancer 
patients with measurable disease are treated with front-
line carboplatin and pacliaxel. Bevacizumub or placebo 
is then added on cycle 2 and continued every 21 days 
for either 6 or 22 cycles. The primary endpoint is overall 
survival and secondary endpoints include progression-free 
survival, toxicity and quality of life. GOG 218 completed 
enrollment in June 2009, having achieved target accrual 
of 2000 patients.25
Bevacizumab is also being investigated as maintenance 
after complete response to second-line treatment. The 
OCEANS trial is 2-part placebo-controlled, randomized, 
multicenter, industry-sponsored phase III study which 
compares bevacizumab in combination with carboplatin/
gemcitabine to the same regimen with placebo in women 
with platinum-sensitive recurrent epithelial ovarian, primary 
peritoneal, or fallopian tube carcinoma.26 In the OCEANS 
protocol, trial participants who demonstrate complete 
response to carboplatin/gemcitabine plus bevacizumab 
or placebo are then offered maintenance treatments with 
bevacizumab or placebo every 3 weeks for 1 year.
Other potent inhibitors of VEGF receptor tyrosine 
kinases are also under phase III investigation. In the front-
line setting is pazopanib, a small-molecule inhibitor of cKit 
which targets platelet derived growth factor receptor as well 
as VEGF receptors 1, 2, and 3. In the AGO-OVAR 16 trial, 
women who have not progressed after first-line chemotherapy 
for epithelial ovarian, fallopian tube, or primary peritoneal 
cancer are randomized to either pazopanib or placebo 
800 mg daily for 52 weeks (12 months). The accrual goal 
is 900 with primary endpoint of progression-free survival 
and secondary endpoints including overall survival, toxicity, 
and quality of life.27
In the setting or recurrence, the drug cediranib will 
soon be under investigation in the ICON6 trial. Cediranib 
(also know as AZD2171) is a once-daily oral therapy which 
targets VEGF 1, 2, and 3 and competes with adenosine 
triphosphate. ICON6 is a multicenter-multiphase trial 
in which patients with recurrent ovarian cancer will be 
randomized to A) carboplatin, paclitaxel and placebo for 
6 cycles followed by placebo maintenance for 18 months; 
B) carboplatin, paclitaxel and cediranib with placebo 
maintenance; or C) carboplatin, paclitaxel and cediranib 
followed by cediranib maintenance. The trial incorporates a 
phase I, II, and III component with accrual goals of 50, 600, 
and 2000 for each phase, respectively.28
Another innovative approach to maintenance involves the 
concept of immunotherapy. The MIMOSA trial (Monoclonal 
antibody Immunotherapy for Malignancies of Ovary by 
Subcutaneous Abagovomab) is a phase III trial involving the 
administration of an antibody which functionally mimics the 
CA125 antigen and induces humoral and cellular CA125-
specific immunity.29 The trial involves repeated vaccination 
every 4 weeks for up to 4 years or until recurrence in ovarian 
cancer patients with complete clinical response to front-
line treatment. MIMOSA has now completed accrual and 
results are anticipated.
Of note, previously published phase III data on the 
related drug oregovamab (a monoclonal antibody to CA125) 
have not demonstrated benefit as either a maintenance or 
a consolidation agent. Berek et al investigated the role of 
maintenance mono-immunotherapy with oregovomab in a 
placebo-controlled blinded trial. Drug or placebo was given 
to ovarian cancer patients after complete clinical response 
from front-line therapy every 4 weeks for 3 cycles and then 
every 12 weeks for 5 years or until recurrence. In a 2:1 
randomization, 251 patients were given drug and 100 given 
placebo, without difference in clinical outcome. A relatively 
modest immune response was seen in participants compared 
to the same drug given in front-line or in recurrent settings 
in combination with other chemotherapies. The authors 
postulated that the maintenance setting may not be the most 
effective time to administer immunotherapy, given the International Journal of Women’s Health 2009:1 178
Hope and Blank Dovepress
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relatively low tumor burden and hence minimal circulating 
tumor antigen targeted by this approach.12,13
Toxicity and quality of life 
considerations
When considering whether to give extended and potentially 
morbid treatments to women in clinical remission, the 
question of quality of life (QoL) must be addressed. Without 
clear evidence of survival advantage, causing patients to 
potentially feel sicker during times of clinical remission 
is of utmost concern. Unfortunately, data addressing the 
impact of maintenance chemotherapy on QoL are currently 
lacking. GOG 178 did not include a QoL component, 
leaving unanswered questions about treatment-associated 
neurotoxicity from prolonged taxane exposure. Markman 
reported major differences in treatment-related sensory 
neuropathy between the 3- and 12-cycle arms of GoG 
178: 35/149 grade 2 events and 9/149 grade 3 events in 
the 12-cycle arm compared with 20/136 grade 2 and 1/136 
grade 3 events in the 3-cycle arm. The trial did not prospec-
tively evaluate the duration of neuropathy or the persistence 
of symptoms after discontinuation of treatment.18
Robinson et al also addressed the taxane question 
in a phase II feasibility trial of paclitaxel maintenance 
therapy following front-line intravenous/intraperitoneal 
(iv/ip) cisplatin/paclitaxel versus iv carboplatin/paclitaxel. 
Robinson found that completion rates of the maintenance 
portion of the regimen were higher in the iv/ip group. 
Patients who stopped maintenance therapy usually stopped 
early (within 3 cycles) and the most common reasons in 
descending order included neuropathy, fatigue, myelosup-
pression, and disease progression.30 The ongoing GOG 212 
does include QoL as a secondary endpoint. In addition, 
a variety of novel taxanes and taxane-like compounds are 
under investigation which may have more acceptable toxicity 
profiles as maintenance agents.22,31–33
Into the future
Looking beyond phase III data, the notion of extended 
chemotherapy treatment is an active area of research extend-
ing far beyond the realm of traditional cytotoxic regimens. 
In a host of ongoing phase I and II trials, polyADP-ribose 
polymerase (PARP) inhibitors, immuno-vaccinations, 
endothelial and epithelial growth factor inhibitors, novel 
VEGF receptor inhibitors, and even concentrated green tea 
are being explored for their potential maintenance benefits 
(see Table 3).34 For patients who want to take proactive 
therapeutic measures to delay recurrence, these maintenance 
trials may offer an opportunity to meet this need. For 
clinicians, these trials represent cutting edge scientific 
efforts to tackle one of the most significant problems 
in ovarian cancer treatment – prevention of recurrence.
Conclusion
The question of the utility of maintenance chemotherapy in 
ovarian cancer has not been answered. Yet there is promising 
research underway and patients should be encouraged to 
participate. Within the coming years, a host of novel more 
targeted and less toxic therapies can be expected to enter 
the line-up for phase III maintenance therapy interrogation.
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